TIM-3 silencing augmented the anti-tumor activity of chimeric antigen receptor-T (CAR-T) cells in vivo. (IMAGE)
Caption
2 × 106 SKOV3 tumor cells expressing luciferase were intraperitoneally inoculated in a xenograft mouse model, and 7 days after inoculation, the 2 × 106 HER2-specific CAR-T kdTim-3 cells or CAR-T cells, or untreated T cells were intraperitoneally administered. (A, B) Tumor growth was monitored using an in vivo imaging system. (C) Survival curve of 80-day post-treatment. ∗P < 0.05 and ∗∗P < 0.01.
Credit
Binglan Zhang, Fuping Zhu, Song Wang, Yong Huang, Shishi Yu, Shaorong Tian, Minmin Li, Pan Li, Qian Xue, Bingqiang Zhang
Usage Restrictions
Credit must be given to the creator. Only noncommercial uses of the work are permitted. No derivatives or adaptations of the work are permitted.
License
CC BY-NC-ND